The Psychedelics Newsletter

Major deals continue positive trajectory for psychedelics in 2024, Psychedelics could treat chronic pain, MDMA research comes under scrutiny

UK advisory body issues rapid response on psychedelics for PTSD, Pilsocybin for chronic pain, Take-home microdosing trial

How clinicians impact patient outcomes in psychedelic therapy, Why it is time for the UK to change laws on psychedelics, How to untangle the ethics of psychedelic care

Traders Betting on ‘Psychedelic Renaissance’, Treating veterans with psychedelics, Microdosing increases neural complexity.

Traders Betting on ‘Psychedelic Renaissance’, Treating veterans with psychedelics, Microdosing increases neural complexity.

Trial to investigate psychedelic candidate for alcohol use disorder, Positive results from BPL-003 in Treatment Resistant Depression, Exploring the latest updates in psychedelic medicine.

Ayahuasca retreats associated with increases in nature-relatedness, What's happening for psychedelics in Europe?, JP Morgan in discussions with psychedelics companies

Investigating neural complexity for altered states, Is there substance behind the psychedelic hype?, Are psychedelics key to expanding consciousness? 

Investigating neural complexity for altered states, Is there substance behind the psychedelic hype?, Are psychedelics key to expanding consciousness? 

MDMA for PTSD receives priority review for New Drug Application, Psychedelic experiences linked with improved sexual function, Sovereign wealth funds in talks to fund biotech groups harnessing psychedelics.